Atara biotherapeutics and pierre fabre enter strategic collaboration to commercialize tabelecleucel (tab-cel®)

South san francisco, calif. & castres, france--(business wire)--atara biotherapeutics, inc. (nasdaq: atra) and pierre fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in europe, middle east, africa, and other select emerging markets for epstein-barr virus (ebv)-positive cancers. atara will retain full rights to tab-cel® in other major markets, including north america, asia pacific, and latin america. under the terms of the agreement, atara will receive
ATRA Ratings Summary
ATRA Quant Ranking